By Colin Kellaher
Compass Therapeutics has hired Barry Shin as the clinical-stage biopharmaceutical company's new chief financial officer.
Compass on Tuesday said Shin most recently served as executive vice president and chief operating and financial officer at biopharmaceutical company Trevena.
Thomas Schuetz, Compass' chief executive, has been serving as the Boston company's principal financial officer.
Compass said Shin, 53 years old, will receive an annual base salary of $475,000, a $50,000 sign-on bonus and an annual bonus with a target of 45% of his base pay.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2024 08:24 ET (13:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.